All In MedTech

FDA Clearance Tracker · P810031-S066

Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD), Healon GV PRO

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 25, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 25, 2020

Approved

Time to decision

261 days

Received Mar 9, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P810031-S066
Device name
Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD), Healon GV PRO
Applicant location
Irvine, CA
Received
Mar 9, 2020
Decided
Nov 25, 2020
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P810031

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

Approval for changes in labeling to include a new Warning, modifications to the Device Description and Precautions, and the addition of two surgical techniques for removal of the Healon GV® PRO OVD from the eye.

Source documents

Other decisions for Johnson & Johnson Surgical Vision, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.